Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 126 to 150 of 903

TitleReference numberPublishedLast updated
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney diseaseTA1035
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)TA1032
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursTA1034
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and overTA1031
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Tebentafusp for treating advanced uveal melanomaTA1027
Ublituximab for treating relapsing multiple sclerosisTA1025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Bevacizumab gamma for treating wet age-related macular degenerationTA1022
Eplontersen for treating hereditary transthyretin-related amyloidosisTA1020
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Avapritinib for treating advanced systemic mastocytosisTA1012

Results per page

  1. 10
  2. 25
  3. 50
  4. All